Life sciences deals in the UK come in several shapes: a university spin-out raising its first institutional round, a biotech out-licensing a programme to a larger partner, or the outright sale of a clinical-stage company. What they share is that the most valuable asset is data, and once a potential partner has seen it, it cannot be unseen. The data room has to release that value in measured steps.
Disclosure happens in stages, tied to contracts
Partnering discussions often start long before any deal is likely. A business development team may talk to a dozen companies at a conference, sign confidentiality agreements with several, and reach a term sheet with one. Each step justifies more disclosure, and each should be a separate permission group rather than a bigger version of the same folder.
Disclosure climbs in steps in a life sciences deal
Before a confidential disclosure agreement, only non-confidential material is shared: a deck and published papers. After the CDA, the partner sees the target product profile and summary data. Once a term sheet is agreed, full study reports, patent file histories and chemistry, manufacturing and controls data go in. Only at the definitive agreement stage do regulator correspondence, raw datasets and supply contracts open up. Large partners may also ask for a clean team arrangement, where commercially sensitive material is seen only by named people who are walled off from competing programmes.
Clinical data and UK GDPR
Health data is special category data under UK GDPR, which means stricter conditions on processing and sharing. Patient-level data from trials should be pseudonymised or anonymised before it goes near a data room, and even pseudonymised data remains personal data if it can be re-identified. The ICO’s guidance on special category data is the starting point, and your trial agreements and consent forms will set further limits on who may see the data.
Ask every provider where data is hosted. Partners are often in the US, Switzerland or Asia, and access from abroad can count as an international transfer. The UK International Data Transfer Agreement or an adequacy decision may be needed, and your data protection officer will want the answer before the first upload.
If the room will hold data that came from the NHS, such as real-world evidence studies, the organisation handling it is usually expected to meet the NHS Data Security and Protection Toolkit standard. Check your data sharing agreement before uploading anything derived from patient records.
Regulatory files buyers will read
A partner’s regulatory team will want to see the full regulatory history: scientific advice from the MHRA and other agencies, clinical trial authorisations, inspection findings and any correspondence about safety. Organise these by agency and by product, with a summary index, because partners will compare what you say in the deck with what the regulator was told.
A pre-upload checklist for scientific data
- Strip patient identifiers and check that remaining fields cannot re-identify anyone
- Confirm that trial agreements and consent forms allow sharing with commercial partners
- Mark every document with its disclosure stage before upload, not after
- Check that university or hospital collaborators have agreed to their data being shared
- Remove draft analyses that contradict the final study report, or label them clearly
- Agree with patent counsel which invention disclosures are safe to share before filing
Spin-outs and university rooms
University spin-outs often hold data across several systems: the founding lab, the technology transfer office and the new company. IP ownership is the first thing investors and partners will test, so the room should contain the assignment or licence from the university, any revenue share terms and evidence that the founders’ prior work is covered. A muddled IP folder costs more time than any other in early-stage biotech diligence.
Mistakes that leak value
The most damaging error is releasing too much too early, for instance raw data to a partner who was only window shopping. Others include uploading a single large folder of study reports with no index, forgetting to switch off access when a partner drops out, and allowing downloads of files that should be view-only. The audit trail is useful here: it shows which partners actually spent time on the data, which often predicts who will bid.
Budget
Life sciences rooms tend to be data-heavy and long-running, sometimes open for a year or more during partnering. Per-page or per-gigabyte pricing can become expensive, so ask for a flat or capped price over a realistic timeframe. Most specialist providers quote rather than publish prices. Our cost guide explains what to compare, and the providers page lists certifications for each.
Questions people ask
Can clinical trial data go in a virtual data room?
Yes, once it has been pseudonymised or anonymised and your trial agreements allow it. Treat it as special category data under UK GDPR, restrict it to the latest disclosure stage, and keep downloads blocked.
What is a clean team in a biotech deal?
A small group of named people at the partner, walled off from competing programmes, who are the only ones allowed to see the most sensitive commercial or scientific data. The room enforces it with a separate permission group.
How long does a licensing data room stay open?
Often longer than an M&A room. Partnering can run for many months before a term sheet, so plan for a year and negotiate pricing that does not penalise a slow process.
Should a spin-out set up a room before its first raise?
Yes, even a simple one. Organising IP assignments, university agreements and key data early saves weeks when investors or partners start diligence.